Folate and B12 in Prostate Cancer

Advances in Clinical Chemistry

Volumn 60, Issue , 2013, Pages 1-63

  Collin, Simon M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cobalamin; Folate metabolism; Folic acid; One carbon metabolic pathway; Prostate cancer

Indexed keywords

BETAINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PROSTATE SPECIFIC ANTIGEN;

BLOOD; DIET; DIET SUPPLEMENTATION; GENETICS; HUMAN; MALE; META ANALYSIS (TOPIC); METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; REVIEW; RISK FACTOR;

BETAINE; DIET; DIETARY SUPPLEMENTS; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; META-ANALYSIS AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; VITAMIN B 12;

MLCS; MLOWN;

EID: 84875113955     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407681-5.00001-5     Document Type: Chapter

References (314)

1. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 1993, 150(2 Pt. 1):379-385.
2. Sakr W.A., Grignon D.J., Crissman J.D., Heilbrun L.K., Cassin B.J., Pontes J.J., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994, 8(3):439-443.
3. Baade P.D., Youlden D.R., Krnjacki L.J. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol. Nutr. Food Res. 2009, 53(2):171-184.
4. Choi S.W., Mason J.B. Folate and carcinogenesis: an integrated scheme. J. Nutr. 2000, 130(2):129-132.
5. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64(6):1975-1986.
6. Yegnasubramanian S., Haffner M.C., Zhang Y., Gurel B., Cornish T.C., Wu Z., et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008, 68(21):8954-8967.
7. Bistulfi G., Vandette E., Matsui S.I., Smiraglia D.J. Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol. 2010, 8(1):6.
8. Kim Y.I. Folate and colorectal cancer: an evidence-based critical review. Mol. Nutr. Food Res. 2007, 51(3):267-292.
9. Mason J.B. Folate, cancer risk, and the Greek god, Proteus: a tale of two chameleons. Nutr. Rev. 2009, 67(4):206-212.
10. Figueiredo J.C., Grau M.V., Haile R.W., Sandler R.S., Summers R.W., Bresalier R.S., et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J. Natl. Cancer Inst. 2009, 101(6):432-435.
11. Pelucchi C., Galeone C., Talamini R., Negri E., Parpinel M., Franceschi S., et al. Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol. Biomarkers Prev. 2005, 14(4):944-948.
12. Rossi E., Hung J., Beilby J.P., Knuiman M.W., Divitini M.L., Bartholomew H. Folate levels and cancer morbidity and mortality: prospective cohort study from Busselton, Western Australia. Ann. Epidemiol. 2006, 16(3):206-212.
13. Shannon J., Phoutrides E., Palma A., Farris P., Peters L., Forester A., et al. Folate intake and prostate cancer risk: a case-control study. Nutr. Cancer 2009, 61(5):617-628.
14. Ebbing M., Bonaa K.H., Nygard O., Arnesen E., Ueland P.M., Nordrehaug J.E., et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009, 302(19):2119-2126.
15. Smith A.D., Kim Y.I., Refsum H. Is folic acid good for everyone?. Am. J. Clin. Nutr. 2008, 87(3):517-533.
16. Mason J.B., Dickstein A., Jacques P.F., Haggarty P., Selhub J., Dallal G., et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol. Biomarkers Prev. 2007, 16(7):1325-1329.
17. Green R. Is it time for vitamin B-12 fortification? What are the questions?. Am. J. Clin. Nutr. 2009, 89(2):712S-716S.
18. Cunha G.R., Alarid E.T., Turner T., Donjacour A.A., Boutin E.L., Foster B.A. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J. Androl. 1992, 13(6):465-475.
19. Platz E.A., Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92(4):237-253.
20. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell. Biochem. 2003, 253(1-2):89-101.
21. Berry P.A., Maitland N.J., Collins A.T. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol. Cell. Endocrinol. 2008, 288(1-2):30-37.
22. Ellem S.J., Risbridger G.P. The dual, opposing roles of estrogen in the prostate. Ann. N. Y. Acad. Sci. 2009, 1155:174-186.
23. McNeal J.E. The zonal anatomy of the prostate. Prostate 1981, 2(1):35-49.
24. Algaba F. Lobar Division of the Prostate. Prostate Cancer in Questions 1991, ICI Publications, Edinburgh, pp. 16-17.
25. Thorpe A., Neal D. Benign prostatic hyperplasia. Lancet 2003, 361(9366):1359-1367.
26. Ramakrishnan K., Salinas R.C. Prostatitis: acute and chronic. Prim. Care 2010, 37(3):547-563.
27. de Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7(4):256-269.
28. Wagenlehner F.M., Elkahwaji J.E., Algaba F., Bjerklund-Johansen T., Naber K.G., Hartung R., et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int. 2007, 100(4):733-737.
29. Nelson W.G., de Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003, 349(4):366-381.
30. Dickinson S.I. Premalignant and malignant prostate lesions: pathologic review. Cancer Control 2010, 17(4):214-222.
31. Schroder F.H., Hermanek P., Denis L., Fair W.R., Gospodarowicz M.K., Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl. 1992, 4:129-138.
32. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.), AJCC Cancer Staging Manual, seventh ed., New Springer, York, NY, 2010. American Joint Committee on Cancer (AJCC) 2010 February 4 (cited 2011 Apr 18). http://www.cancerstaging.org.
33. Lilja H. A Kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal-vesicle protein. J. Clin. Invest. 1985, 76(5):1899-1903.
34. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987, 317(15):909-916.
35. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991, 324(17):1156-1161.
36. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl. Cancer Inst. 2009, 101(19):1325-1329.
37. Thompson I.M., Ankerst D.P. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007, 176(13):1853-1858.
38. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.
39. Rogers C.G., Khan M.A., Craig M.M., Veltri R.W., Partin A.W. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004, 101(11):2549-2556.
40. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294(4):433-439.
41. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J. Natl. Cancer Inst. 2003, 95(18):1376-1383.
42. van den Bergh R.C., Roemeling S., Roobol M.J., Wolters T., Schroder F.H., Bangma C.H. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer-a review. Eur. Urol. 2008, 54(3):505-516.
43. Martin R.M., Gunnell D., Hamdy F., Neal D., Lane A., Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J. Urol. 2006, 176(2):439-449.
44. Metcalfe C., Tilling K., Davis M., Lane J.A., Martin R.M., Kynaston H., et al. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. Br. J. Cancer 2009, 101(3):390-394.
45. Tilling K., Garmo H., Metcalfe C., Holmberg L., Hamdy F.C., Neal D.E., et al. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. Eur. Urol. 2010, 57(3):446-452.
46. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 2004, 13(Spec. No. 1):R103-R121.
47. Page W.F., Braun M.M., Partin A.W., Caporaso N., Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997, 33(4):240-245.
48. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000, 343(2):78-85.
49. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol. Biomarkers Prev. 2001, 10(7):733-741.
50. Chu K.C., Tarone R.E., Freeman H.P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003, 97(6):1507-1516.
51. Ben-Shlomo Y., Evans S., Ibrahim F., Patel B., Anson K., Chinegwundoh F., et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur. Urol. 2008, 53(1):99-105.
52. Collin S.M., Metcalfe C., Donovan J., Lane J.A., Davis M., Neal D., et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008, 102(10):1400-1406.
53. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 1994, 151(5):1283-1290.
54. Jakobsson L., Loven L., Hallberg I.R. Micturition problems in relation to quality of life in men with prostate cancer or benign prostatic hyperplasia: comparison with men from the general population. Cancer Nurs. 2004, 27(3):218-229.
55. Nam R.K., Toi A., Klotz L.H., Trachtenberg J., Jewett M.A., Appu S., et al. Assessing individual risk for prostate cancer. J. Clin. Oncol. 2007, 25(24):3582-3588.
56. Porter C.R., Latchamsetty K.C., Coogan C.L., Kim J. Absence of lower urinary tract symptoms is an independent predictor for cancer at prostate biopsy, but prostate-specific antigen is not: results from a prospective series of 569 patients. Clin. Prostate Cancer 2005, 4(1):50-54.
57. Loft S., Poulsen H.E. Cancer risk and oxidative DNA damage in man. J. Mol. Med. 1996, 74(6):297-312.
58. Bostwick D.G., Alexander E.E., Singh R., Shan A., Qian J., Santella R.M., et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000, 89(1):123-134.
59. Olinski R., Zastawny T.H., Foksinski M., Barecki A., Dizdaroglu M. DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic. Biol. Med. 1995, 18(4):807-813.
60. Pace G., Di M.C., De A.D., Corbacelli C., Di R.L., Vicentini C., et al. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol. Int. 2010, 85(3):328-333.
61. Chan J.M., Gann P.H., Giovannucci E.L. Role of diet in prostate cancer development and progression. J. Clin. Oncol. 2005, 23(32):8152-8160.
62. Gaziano J.M., Glynn R.J., Christen W.G., Kurth T., Belanger C., MacFadyen J., et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009, 301(1):52-62.
63. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301(1):39-51.
64. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
65. Mannervik B., Board P.G., Hayes J.D., Listowsky I., Pearson W.R. Nomenclature for mammalian soluble glutathione transferases. Methods Enzymol. 2005, 401:1-8.
66. Lin X., Tascilar M., Lee W.H., Vles W.J., Lee B.H., Veeraswamy R., et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 2001, 159(5):1815-1826.
67. Nakayama M., Bennett C.J., Hicks J.L., Epstein J.I., Platz E.A., Nelson W.G., et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 2003, 163(3):923-933.
68. Nakayama M., Gonzalgo M.L., Yegnasubramanian S., Lin X., de Marzo A.M., Nelson W.G. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 2004, 91(3):540-552.
69. Bastian P.J., Palapattu G.S., Lin X., Yegnasubramanian S., Mangold L.A., Trock B., et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 2005, 11(11):4037-4043.
70. Dhillon V.S., Shahid M., Husain S.A. Associations of MTHFR DNMT3b 4977 bp deletion in mtDNA and GSTM1 deletion, and aberrant CpG island hypermethylation of GSTM1 in non-obstructive infertility in Indian men. Mol. Hum. Reprod. 2007, 13(4):213-222.
71. Pandey M., Shukla S., Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int. J. Cancer 2010, 126(11):2520-2533.
72. Woodson K., Hayes R., Wideroff L., Villaruz L., Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 2003, 55(3):199-205.
73. Mo Z., Gao Y., Cao Y., Gao F., Jian L. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 2009, 69(6):662-688.
74. Nock N.L., Bock C., Neslund-Dudas C., Beebe-Dimmer J., Rundle A., Tang D., et al. Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control 2009, 20(10):1915-1926.
75. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, World Cancer Research Fund/American Institute for Cancer Research, Washington, DC, 2007.
76. Hanson A.D., Roje S. One-carbon metabolism in higher plants. Annu. Rev. Plant Physiol. Plant Mol. Biol. 2001, 52:119-137.
77. Hanson A.D., Gregory J.F. Synthesis and turnover of folates in plants. Curr. Opin. Plant Biol. 2002, 5(3):244-249.
78. Scott J., Rébeillé F., Fletcher J., Flicker L. Folic acid and folates: the feasibility for nutritional enhancement in plant foods. J. Sci. Food Agric. 2000, 80(7):795-824.
79. Scott J.M. Folate and vitamin B12. Proc. Nutr. Soc. 1999, 58(2):441-448.
80. Halsted C.H. Jejunal brush-border folate hydrolase. A novel enzyme. West. J. Med. 1991, 155(6):605-609.
81. Darcy-Vrillon B., Selhub J., Rosenberg I.H. Analysis of sequential events in intestinal absorption of folylpolyglutamate. Am. J. Physiol. 1988, 255(3 Pt. 1):G361-G366.
82. Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993, 53(2):227-230.
83. Ghosh A., Heston W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004, 91(3):528-539.
84. Haffner M.C., Kronberger I.E., Ross J.S., Sheehan C.E., Zitt M., Muhlmann G., et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. 2009, 40(12):1754-1761.
85. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein?. Am. J. Physiol. Cell Physiol. 2005, 288(5):C975-C981.
86. Qiu A., Jansen M., Sakaris A., Min S.H., Chattopadhyay S., Tsai E., et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006, 127(5):917-928.
87. Yuasa H., Inoue K., Hayashi Y. Molecular and functional characteristics of proton-coupled folate transporter. J. Pharm. Sci. 2009, 98(5):1608-1616.
88. Tarr P.T., Tarling E.J., Bojanic D.D., Edwards P.A., Baldan A. Emerging new paradigms for ABCG transporters. Biochim. Biophys. Acta 2009, 1791(7):584-593.
89. Stefkova J., Poledne R., Hubacek J.A. ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol. Res. 2004, 53(3):235-243.
90. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 2006, 6(4):350-354.
91. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007, 26(1):153-181.
92. Sanchez C., Mendoza P., Contreras H.R., Vergara J., McCubrey J.A., Huidobro C., et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009, 69(13):1448-1459.
93. van Brussel J.P., van Steenbrugge G.J., van Krimpen C., Bogdanowicz J.F.A.T., van der Kwast T.H., Schroder F.H., et al. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J. Urol. 2001, 165(1):130-135.
94. Matherly L.H., Hou Z. Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitam. Horm. 2008, 79:145-184.
95. Lapenta V., Sossi V., Gosset P., Vayssettes C., Vitali T., Rabatel N., et al. Construction of a 2.5-Mb integrated physical and gene map of distal 21q22.3. Genomics 1998, 49(1):1-13.
96. Henderson G.B. Folate-binding proteins. Annu. Rev. Nutr. 1990, 10:319-335.
97. Solanky N., Requena J.A., D'Souza S.W., Sibley C.P., Glazier J.D. Expression of folate transporters in human placenta and implications for homocysteine metabolism. Placenta 2010, 31(2):134-143.
98. Birn H. The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. Am. J. Physiol. Renal Physiol. 2006, 291(1):F22-F36.
99. Kelemen L.E. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?. Int. J. Cancer 2006, 119(2):243-250.
100. Birn H., Zhai X., Holm J., Hansen S.I., Jacobsen C., Christensen E.I., et al. Megalin binds and mediates cellular internalization of folate binding protein. FEBS J. 2005, 272(17):4423-4430.
101. Chen L., Qi H., Korenberg J., Garrow T.A., Choi Y.J., Shane B. Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. J. Biol. Chem. 1996, 271(22):13077-13087.
102. McGuire J.J., Bertino J.R. Enzymatic synthesis and function of folylpolyglutamates. Mol. Cell. Biochem. 1981, 38(Spec. No. (Pt. 1)):19-48.
103. Ifergan I., Assaraf Y.G. Molecular mechanisms of adaptation to folate deficiency. Vitam. Horm. 2008, 79:99-143.
104. McKillop D.J., McNulty H., Scott J.M., McPartlin J.M., Strain J.J., Bradbury I., et al. The rate of intestinal absorption of natural food folates is not related to the extent of folate conjugation. Am. J. Clin. Nutr. 2006, 84(1):167-173.
105. McNulty H., Pentieva K. Folate bioavailability. Proc. Nutr. Soc. 2004, 63(4):529-536.
106. Sweeney M.R., Staines A., Daly L., Traynor A., Daly S., Bailey S.W., et al. Persistent circulating unmetabolised folic acid in a setting of liberal voluntary folic acid fortification. Implications for further mandatory fortification?. BMC Public Health 2009, 9:295.
107. Kelly P., McPartlin J., Goggins M., Weir D.G., Scott J.M. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am. J. Clin. Nutr. 1997, 65(6):1790-1795.
108. Bailey S.W., Ayling J.E. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(36):15424-15429.
109. Wills L. Treatment of " pernicious anaemia of pregnancy" and " tropical anaemia" with special reference to yeast extract as a curative agent. BMJ 1931, 1:1059-1064.
110. Mitchell H.K., Snell E.E., Williams R.J. The concentration of 'folic acid'. J. Am. Chem. Soc. 1941, 63:2284.
111. Angier R.B., Boothe J.H., Hutchings B.L., Mowat J.H., Semb J., Stokstad E.L., et al. The structure and synthesis of the liver L. casei factor. Science 1946, 103(2683):667-669.
112. Spray G.H. The role of pteroylglutamic acid and related compounds in macrocytic anaemia. Proc. Nutr. Soc. 1956, 15(2):119-126.
113. Chanarin I. Historical review: a history of pernicious anaemia. Br. J. Haematol. 2000, 111(2):407-415.
114. Smith E.L. The discovery and identification of vitamin B12. Br. J. Nutr. 1952, 6(3):295-299.
115. Scott A.I. Discovering nature's diverse pathways to vitamin B12: a 35-year odyssey. J. Org. Chem. 2003, 68(7):2529-2539.
116. Christensen E.I., Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat. Rev. Mol. Cell Biol. 2002, 3(4):256-266.
117. Sennett C., Rosenberg L.E., Mellman I.S. Transmembrane transport of cobalamin in prokaryotic and eukaryotic cells. Annu. Rev. Biochem. 1981, 50:1053-1086.
118. Regec A., Quadros E.V., Platica O., Rothenberg S.P. The cloning and characterization of the human transcobalamin II gene. Blood 1995, 85(10):2711-2719.
119. Hvas A.M., Nexo E. Holotranscobalamin-a first choice assay for diagnosing early vitamin B deficiency?. J. Intern. Med. 2005, 257(3):289-298.
120. Refsum H., Johnston C., Guttormsen A.B., Nexo E. Holotranscobalamin and total transcobalamin in human plasma: determination, determinants, and reference values in healthy adults. Clin. Chem. 2006, 52(1):129-137.
121. Burger R.L., Schneider R.J., Mehlman C.S., Allen R.H. Human plasma R-type vitamin B12-binding proteins. II. The role of transcobalamin I, transcobalamin III, and the normal granulocyte vitamin B12-binding protein in the plasma transport of vitamin B12. J. Biol. Chem. 1975, 250(19):7707-7713.
122. Burger R.L., Mehlman C.S., Allen R.H. Human plasma R-type vitamin B12-binding proteins. I. Isolation and characterization of transcobalamin I. TRANSCOBALAMIN III and the normal granulocyte vitamin B12-binding protein. J. Biol. Chem. 1975, 250(19):7700-7706.
123. Hardlei T.F., Nexo E. A new principle for measurement of cobalamin and corrinoids, used for studies of cobalamin analogs on serum haptocorrin. Clin. Chem. 2009, 55(5):1002-1010.
124. Carmel R. Mild transcobalamin I (haptocorrin) deficiency and low serum cobalamin concentrations. Clin. Chem. 2003, 49(8):1367-1374.
125. Carmel R., Parker J., Kelman Z. Genomic mutations associated with mild and severe deficiencies of transcobalamin I (haptocorrin) that cause mildly and severely low serum cobalamin levels. Br. J. Haematol. 2009, 147(3):386-391.
126. Morkbak A.L., Poulsen S.S., Nexo E. Haptocorrin in humans. Clin. Chem. Lab. Med. 2007, 45(12):1751-1759.
127. Carmel R., Eisenberg L. Serum vitamin B12 and transcobalamin abnormalities in patients with cancer. Cancer 1977, 40(3):1348-1353.
128. Ermens A.A., Vlasveld L.T., Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin. Biochem. 2003, 36(8):585-590.
129. Vlasveld L.T., Bos G.M., Ermens A.A., Bakker J.A., Lindemans J. Hyperhomocysteinemia and functional cobalamin deficiency due to granulocytosis-induced alterations in the cobalamin-binding protein. Haematologica 2006, 91(3):394-396.
130. Seetharam B., Yammani R.R. Cobalamin transport proteins and their cell-surface receptors. Expert Rev. Mol. Med. 2003, 5(18):1-18.
131. Breitfeld P.P., Simmons C.F., Strous G.J., Geuze H.J., Schwartz A.L. Cell biology of the asialoglycoprotein receptor system: a model of receptor-mediated endocytosis. Int. Rev. Cytol. 1985, 97:47-95.
132. Seetharam B., Li N. Transcobalamin II and its cell surface receptor. Vitam. Horm. 2000, 59:337-366.
133. Quadros E.V., Nakayama Y., Sequeira J.M. The protein and the gene encoding the receptor for the cellular uptake of transcobalamin-bound cobalamin. Blood 2009, 113(1):186-192.
134. Seetharam B. Receptor-mediated endocytosis of cobalamin (vitamin B12). Annu. Rev. Nutr. 1999, 19:173-195.
135. Refsum H., Smith A.D. Are we ready for mandatory fortification with vitamin B-12?. Am. J. Clin. Nutr. 2008, 88(2):253-254.
136. Green R., Miller J.W. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population. Clin. Chem. Lab. Med. 2005, 43(10):1048-1051.
137. Ueland P.M., Refsum H., Beresford S.A., Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 2000, 72(2):324-332.
138. Stipanuk M.H. Metabolism of sulfur-containing amino acids. Annu. Rev. Nutr. 1986, 6:179-209.
139. Chiang P.K., Gordon R.K., Tal J., Zeng G.C., Doctor B.P., Pardhasaradhi K., et al. S-Adenosylmethionine and methylation. FASEB J. 1996, 10(4):471-480.
140. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10(5):295-304.
141. Persson L. Polyamine homoeostasis. Essays Biochem. 2009, 46:11-24.
142. Pegg A.E. Mammalian polyamine metabolism and function. IUBMB Life 2009, 61(9):880-894.
143. Childs A.C., Mehta D.J., Gerner E.W. Polyamine-dependent gene expression. Cell. Mol. Life Sci. 2003, 60(7):1394-1406.
144. Alm K., Oredsson S. Cells and polyamines do it cyclically. Essays Biochem. 2009, 46:63-76.
145. Rial N.S., Meyskens F.L., Gerner E.W. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. Essays Biochem. 2009, 46:111-124.
146. Mason J.B. Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J. Nutr. 2003, 133(Suppl. 3):941S-947S.
147. Brosnan J.T., Brosnan M.E. The sulfur-containing amino acids: an overview. J. Nutr. 2006, 136(Suppl. 6):1636S-1640S.
148. Nijhout H.F., Reed M.C., Anderson D.F., Mattingly J.C., James S.J., Ulrich C.M. Long-range allosteric interactions between the folate and methionine cycles stabilize DNA methylation reaction rate. Epigenetics 2006, 1(2):81-87.
149. Ueland P.M., Holm P.I., Hustad S. Betaine: a key modulator of one-carbon metabolism and homocysteine status. Clin. Chem. Lab. Med. 2005, 43(10):1069-1075.
150. Zeisel S.H., Mar M.H., Howe J.C., Holden J.M. Concentrations of choline-containing compounds and betaine in common foods. J. Nutr. 2003, 133(5):1302-1307.
151. Zeisel S.H., Blusztajn J.K. Choline and human nutrition. Annu. Rev. Nutr. 1994, 14:269-296.
152. Lee J.E., Jacques P.F., Dougherty L., Selhub J., Giovannucci E., Zeisel S.H., et al. Are dietary choline and betaine intakes determinants of total homocysteine concentration?. Am. J. Clin. Nutr. 2010, 91(5):1303-1310.
153. Pajares M.A., Perez-Sala D. Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism?. Cell. Mol. Life Sci. 2006, 63(23):2792-2803.
154. MacCoss M.J., Fukagawa N.K., Matthews D.E. Measurement of intracellular sulfur amino acid metabolism in humans. Am. J. Physiol. Endocrinol. Metab. 2001, 280(6):E947-E955.
155. Refsum H., Nurk E., Smith A.D., Ueland P.M., Gjesdal C.G., Bjelland I., et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J. Nutr. 2006, 136(Suppl. 6):1731S-1740S.
156. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J. Nutr. 2006, 136(Suppl. 6):1726S-1730S.
157. Molloy A.M. Folate and homocysteine interrelationships including genetics of the relevant enzymes. Curr. Opin. Lipidol. 2004, 15(1):49-57.
158. Banerjee R.V., Matthews R.G. Cobalamin-dependent methionine synthase. FASEB J. 1990, 4(5):1450-1459.
159. Goulding C.W., Postigo D., Matthews R.G. Cobalamin-dependent methionine synthase is a modular protein with distinct regions for binding homocysteine, methyltetrahydrofolate, cobalamin, and adenosylmethionine. Biochemistry 1997, 36(26):8082-8091.
160. Garrow T.A., Brenner A.A., Whitehead V.M., Chen X.N., Duncan R.G., Korenberg J.R., et al. Cloning of human cDNAs encoding mitochondrial and cytosolic serine hydroxymethyltransferases and chromosomal localization. J. Biol. Chem. 1993, 268(16):11910-11916.
161. Christensen K.E., Mackenzie R.E. Mitochondrial methylenetetrahydrofolate dehydrogenase, methenyltetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetases. Vitam. Horm. 2008, 79:393-410.
162. Appling D.R. Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J. 1991, 5(12):2645-2651.
163. Christensen K.E., Mackenzie R.E. Mitochondrial one-carbon metabolism is adapted to the specific needs of yeast, plants and mammals. Bioessays 2006, 28(6):595-605.
164. Prem veer R.G., Pardee A.B. Multienzyme complex for metabolic channeling in mammalian DNA replication. Proc. Natl. Acad. Sci. U. S. A. 1980, 77(6):3312-3316.
165. An S., Kumar R., Sheets E.D., Benkovic S.J. Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. Science 2008, 320(5872):103-106.
166. Anderson D.D., Woeller C.F., Stover P.J. Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase. Clin. Chem. Lab. Med. 2007, 45(12):1760-1763.
167. Woeller C.F., Anderson D.D., Szebenyi D.M., Stover P.J. Evidence for small ubiquitin-like modifier-dependent nuclear import of the thymidylate biosynthesis pathway. J. Biol. Chem. 2007, 282(24):17623-17631.
168. Herbig K., Chiang E.P., Lee L.R., Hills J., Shane B., Stover P.J. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J. Biol. Chem. 2002, 277(41):38381-38389.
169. Goyette P., Sumner J.S., Milos R., Duncan A.M., Rosenblatt D.S., Matthews R.G., et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat. Genet. 1994, 7(2):195-200.
170. Goyette P., Pai A., Milos R., Frosst P., Tran P., Chen Z., et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm. Genome 1998, 9(8):652-656.
171. Martin Y.N., Salavaggione O.E., Eckloff B.W., Wieben E.D., Schaid D.J., Weinshilboum R.M. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet. Genomics 2006, 16(4):265-277.
172. Rosenblatt D.S., Fenton W.A. Inherited disorders of folate and cobalamin transport and metabolism. The Metabolic & Molecular Bases of Inherited Disease 2001, 3897-3933. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
173. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10(1):111-113.
174. van der Put N.M., Gabreels F., Stevens E.M., Smeitink J.A., Trijbels F.J., Eskes T.K., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am. J. Hum. Genet. 1998, 62(5):1044-1051.
175. Wilcken B., Bamforth F., Li Z., Zhu H., Ritvanen A., Renlund M., et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 2003, 40(8):619-625.
176. Selhub J. Homocysteine metabolism. Annu. Rev. Nutr. 1999, 19:217-246.
177. Bagley P.J., Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(22):13217-13220.
178. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93(1):7-9.
179. Girelli D., Friso S., Trabetti E., Olivieri O., Russo C., Pessotto R., et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998, 91(11):4158-4163.
180. Yang Q.H., Botto L.D., Gallagher M., Friedman J.M., Sanders C.L., Koontz D., et al. Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank. Am. J. Clin. Nutr. 2008, 88(1):232-246.
181. Choi S.W., Friso S. Interaction between folate and methylene-tetrahydrofolate reductase gene in cancer. Nutrient-Gene Interactions in Cancer 2006, 57-74. CRC Press, Boca Raton, FL. S.W. Choi, S. Friso (Eds.).
182. Luka Z., Mudd S.H., Wagner C. Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J. Biol. Chem. 2009, 284(34):22507-22511.
183. Huang Y.C., Lee C.M., Chen M., Chung M.Y., Chang Y.H., Huang W.J., et al. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin. Cancer Res. 2007, 13(5):1412-1420.
184. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457(7231):910-914.
185. Fowler B. Genetic defects of folate and cobalamin metabolism. Eur. J. Pediatr. 1998, 157(Suppl. 2):S60-S66.
186. Blount B.C., Mack M.M., Wehr C.M., MacGregor J.T., Hiatt R.A., Wang G., et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(7):3290-3295.
187. Duthie S.J., Narayanan S., Blum S., Pirie L., Brand G.M. Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr. Cancer 2000, 37(2):245-251.
188. Linhart H.G., Troen A., Bell G.W., Cantu E., Chao W.H., Moran E., et al. Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology 2009, 136(1):227-235.
189. DeVos L., Chanson A., Liu Z., Ciappio E.D., Parnell L.D., Mason J.B., et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am. J. Clin. Nutr. 2008, 88(4):1149-1158.
190. Sohn K.J., Jang H., Campan M., Weisenberger D.J., Dickhout J., Wang Y.C., et al. The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. Int. J. Cancer 2009, 124(9):1999-2005.
191. Auerbach P., Bennett R.A., Bailey E.A., Krokan H.E., Demple B. Mutagenic specificity of endogenously generated abasic sites in Saccharomyces cerevisiae chromosomal DNA. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(49):17711-17716.
192. Kouzminova E.A., Kuzminov A. Patterns of chromosomal fragmentation due to uracil-DNA incorporation reveal a novel mechanism of replication-dependent double-stranded breaks. Mol. Microbiol. 2008, 68(1):202-215.
193. Shen J.C., Rideout W.M., Jones P.A. High frequency mutagenesis by a DNA methyltransferase. Cell 1992, 71(7):1073-1080.
194. Lutsenko E., Bhagwat A.S. Principal causes of hot spots for cytosine to thymine mutations at sites of cytosine methylation in growing cells. A model, its experimental support and implications. Mutat. Res. 1999, 437(1):11-20.
195. Cooper D.N., Youssoufian H. The CpG dinucleotide and human genetic disease. Hum. Genet. 1988, 78(2):151-155.
196. Waddington C.H. Organisers and Genes 1940, Cambridge University Press.
197. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31(1):27-36.
198. Dobosy J.R., Roberts J.L., Fu V.X., Jarrard D.F. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 2007, 177(3):822-831.
199. Schulz W.A., Hoffmann M.J. Epigenetic mechanisms in the biology of prostate cancer. Semin. Cancer Biol. 2009, 19(3):172-180.
200. Davidsson J., Lilljebjorn H., Andersson A., Veerla S., Heldrup J., Behrendtz M., et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum. Mol. Genet. 2009, 18(21):4054-4065.
201. Nelson W.G., de Marzo A.M., Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009, 150(9):3991-4002.
202. Ross S.A. Diet and DNA methylation interactions in cancer prevention. Ann. N. Y. Acad. Sci. 2003, 983:197-207.
203. Cooper D.N. Eukaryotic DNA, methylation. Hum. Genet. 1983, 64(4):315-333.
204. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3(4):253-266.
205. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321(6067):209-213.
206. Jia D., Cheng X. Methylation on the nucleosome. Nutrients and Epigenetics 2009, 7-36. CRC Press, Boca Raton, FL. S.W. Choi, S. Friso (Eds.).
207. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21(1):103-107.
208. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3(6):415-428.
209. Jacinto F.V., Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007, 22(4):247-253.
210. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24(2):132-138.
211. Park J.Y. Promoter hypermethylation in prostate cancer. Cancer Control 2010, 17(4):245-255.
212. Phe V., Cussenot O., Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int. 2010, 105(10):1364-1370.
213. Roupret M., Hupertan V., Catto J.W., Yates D.R., Rehman I., Proctor L.M., et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 2008, 122(4):952-956.
214. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301(5895):89-92.
215. Hoffmann M.J., Schulz W.A. Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 2005, 83(3):296-321.
216. Szpakowski S., Sun X., Lage J.M., Dyer A., Rubinstein J., Kowalski D., et al. Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene 2009, 448(2):151-167.
217. Ogino S., Kawasaki T., Nosho K., Ohnishi M., Suemoto Y., Kirkner G.J., et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int. J. Cancer 2008, 122(12):2767-2773.
218. Schulz W.A., Steinhoff C., Florl A.R. Methylation of endogenous human retroelements in health and disease. Curr. Top. Microbiol. Immunol. 2006, 310:211-250.
219. Florl A.R., Lower R., Schmitz-Drager B.J., Schulz W.A. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br. J. Cancer 1999, 80(9):1312-1321.
220. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21(35):5400-5413.
221. Kaneda A., Tsukamoto T., Takamura-Enya T., Watanabe N., Kaminishi M., Sugimura T., et al. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci. 2004, 95(1):58-64.
222. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1(2):239-259.
223. Schulz W.A., Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J. Cell. Mol. Med. 2006, 10(1):100-125.
224. Kawamoto K., Okino S.T., Place R.F., Urakami S., Hirata H., Kikuno N., et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin. Cancer Res. 2007, 13(9):2541-2548.
225. Abbas A., Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008, 3(6):300-309.
226. Ellinger J., Kahl P., von der G.J., Rogenhofer S., Heukamp L.C., Gutgemann I., et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70(1):61-69.
227. Shi X.B., Tepper C.G., White R.W. MicroRNAs and prostate cancer. J. Cell. Mol. Med. 2008, 12(5A):1456-1465.
228. Sun R., Fu X., Li Y., Xie Y., Mao Y. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 2009, 10:93.
229. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126(5):1166-1176.
230. Slatkin M. Epigenetic inheritance and the missing heritability problem. Genetics 2009, 182(3):845-850.
231. Wolff G.L., Kodell R.L., Moore S.R., Cooney C.A. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J. 1998, 12(11):949-957.
232. Waterland R.A., Jirtle R.L. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 2003, 23(15):5293-5300.
233. Miltenberger R.J., Mynatt R.L., Wilkinson J.E., Woychik R.P. The role of the agouti gene in the yellow obese syndrome. J. Nutr. 1997, 127(9):1902S-1907S.
234. Klebig M.L., Wilkinson J.E., Geisler J.G., Woychik R.P. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(11):4728-4732.
235. Dolinoy D.C., Weidman J.R., Waterland R.A., Jirtle R.L. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect. 2006, 114(4):567-572.
236. Hong T., Nakagawa T., Pan W., Kim M.Y., Kraus W.L., Ikehara T., et al. Isoflavones stimulate estrogen receptor-mediated core histone acetylation. Biochem. Biophys. Res. Commun. 2004, 317(1):259-264.
237. Pogribny I.P., Rusyn I., Beland F.A. Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. Environ. Mol. Mutagen. 2008, 49(1):9-15.
238. Pogribny I.P., Muskhelishvili L., Miller B.J., James S.J. Presence and consequence of uracil in preneoplastic DNA from folate/methyl-deficient rats. Carcinogenesis 1997, 18(11):2071-2076.
239. Pogribny I.P., James S.J., Jernigan S., Pogribna M. Genomic hypomethylation is specific for preneoplastic liver in folate/methyl deficient rats and does not occur in non-target tissues. Mutat. Res. 2004, 548(1-2):53-59.
240. Pogribny I.P., Ross S.A., Wise C., Pogribna M., Jones E.A., Tryndyak V.P., et al. Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat. Res. 2006, 593(1-2):80-87.
241. Pogribny I.P., James S.J. De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Cancer Lett. 2002, 187(1-2):69-75.
242. Ghoshal K., Li X., Datta J., Bai S., Pogribny I., Pogribny M., et al. A folate- and methyl-deficient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 rats. J. Nutr. 2006, 136(6):1522-1527.
243. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99(3):671-678.
244. Pogribny I.P., Ross S.A., Tryndyak V.P., Pogribna M., Poirier L.A., Karpinets T.V. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006, 27(6):1180-1186.
245. Kim Y.I. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ. Mol. Mutagen. 2004, 44(1):10-25.
246. Kim Y.I. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer?. Cancer Epidemiol. Biomarkers Prev. 2004, 13(4):511-519.
247. Rampersaud G.C., Kauwell G.P., Hutson A.D., Cerda J.J., Bailey L.B. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am. J. Clin. Nutr. 2000, 72(4):998-1003.
248. Jacob R.A., Gretz D.M., Taylor P.C., James S.J., Pogribny I.P., Miller B.J., et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J. Nutr. 1998, 128(7):1204-1212.
249. Fowler B.M., Giuliano A.R., Piyathilake C., Nour M., Hatch K. Hypomethylation in cervical tissue: is there a correlation with folate status?. Cancer Epidemiol. Biomarkers Prev. 1998, 7(10):901-906.
250. Shelnutt K.P., Kauwell G.P., Gregory J.F., Maneval D.R., Quinlivan E.P., Theriaque D.W., et al. Methylenetetrahydrofolate reductase 677C->T polymorphism affects DNA methylation in response to controlled folate intake in young women. J. Nutr. Biochem. 2004, 15(9):554-560.
251. Friso S., Choi S.W., Girelli D., Mason J.B., Dolnikowski G.G., Bagley P.J., et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(8):5606-5611.
252. Narayanan S., McConnell J., Little J., Sharp L., Piyathilake C.J., Powers H., et al. Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo. Cancer Epidemiol. Biomarkers Prev. 2004, 13(9):1436-1443.
253. Brunaud L., Alberto J.M., Ayav A., Gerard P., Namour F., Antunes L., et al. Vitamin B12 is a strong determinant of low methionine synthase activity and DNA hypomethylation in gastrectomized rats. Digestion 2003, 68(2-3):133-140.
254. Choi S.W., Friso S., Ghandour H., Bagley P.J., Selhub J., Mason J.B. Vitamin B-12 deficiency induces anomalies of base substitution and methylation in the DNA of rat colonic epithelium. J. Nutr. 2004, 134(4):750-755.
255. Piyathilake C.J., Johanning G.L., Macaluso M., Whiteside M., Oelschlager D.K., Heimburger D.C., et al. Localized folate and vitamin B-12 deficiency in squamous cell lung cancer is associated with global DNA hypomethylation. Nutr. Cancer 2000, 37(1):99-107.
256. Al-Ghnaniem R., Peters J., Foresti R., Heaton N., Pufulete M. Methylation of estrogen receptor alpha and mutL homolog 1 in normal colonic mucosa: association with folate and vitamin B-12 status in subjects with and without colorectal neoplasia. Am. J. Clin. Nutr. 2007, 86(4):1064-1072.
257. Huang S. Histone methyltransferases, diet nutrients and tumour suppressors. Nat. Rev. Cancer 2002, 2(6):469-476.
258. Choi S.W., Corrocher R., Friso S. Nutrients and DNA methylation. Nutrients and Epigenetics 2009, 105-125. CRC Press, Boca Raton, FL. S.W. Choi, S. Friso (Eds.).
259. Ross S.A. Nutrition, epigenetics, and cancer. Nutrients and Epigenetics 2009, 207-228. CRC Press, Boca Raton, FL. S.W. Choi, S. Friso (Eds.).
260. Majid S., Dar A.A., Shahryari V., Hirata H., Ahmad A., Saini S., et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 2010, 116(1):66-76.
261. King-Batoon A., Leszczynska J.M., Klein C.B. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen. 2008, 49(1):36-45.
262. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat. Res. 2001, 475(1-2):57-67.
263. Fenech M., Rinaldi J. The relationship between micronuclei in human lymphocytes and plasma levels of vitamin C, vitamin E, vitamin B12 and folic acid. Carcinogenesis 1994, 15(7):1405-1411.
264. Fenech M., Aitken C., Rinaldi J. Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis 1998, 19(7):1163-1171.
265. Fenech M.F., Dreosti I.E., Rinaldi J.R. Folate, vitamin B12, homocysteine status and chromosome damage rate in lymphocytes of older men. Carcinogenesis 1997, 18(7):1329-1336.
266. Christensen B.C., Houseman E.A., Marsit C.J., Zheng S., Wrensch M.R., Wiemels J.L., et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009, 5(8):e1000602.
267. Casillas M.A., Lopatina N., Andrews L.G., Tollefsbol T.O. Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts. Mol. Cell. Biochem. 2003, 252(1-2):33-43.
268. Lopatina N., Haskell J.F., Andrews L.G., Poole J.C., Saldanha S., Tollefsbol T. Differential maintenance and de novo methylating activity by three DNA methyltransferases in aging and immortalized fibroblasts. J. Cell. Biochem. 2002, 84(2):324-334.
269. Jang H., Mason J.B., Choi S.W. Genetic and epigenetic interactions between folate and aging in carcinogenesis. J. Nutr. 2005, 135(Suppl. 12):2967S-2971S.
270. Mason J.B., Choi S.W., Liu Z. Other one-carbon micronutrients and age modulate the effects of folate on colorectal carcinogenesis. Nutr. Rev. 2008, 66(Suppl. 1):S15-S17.
271. Kim J., Kim J.Y., Song K.S., Lee Y.H., Seo J.S., Jelinek J., et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim. Biophys. Acta 2007, 1772(1):72-80.
272. Issa J.P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., Baylin S.B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 1994, 7(4):536-540.
273. Kwabi-Addo B., Chung W., Shen L., Ittmann M., Wheeler T., Jelinek J., et al. Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 2007, 13(13):3796-3802.
274. Ding S.Z., Goldberg J.B., Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol. 2010, 6(5):851-862.
275. Agrawal A., Tay J., Yang G.E., Agrawal S., Gupta S. Age-associated epigenetic modifications in human DNA increase its immunogenicity. Aging (Albany, NY) 2010, 2(2):93-100.
276. Giovannucci E., Ogino S. DNA methylation, field effects, and colorectal cancer. J. Natl. Cancer Inst. 2005, 97(18):1317-1319.
277. Nonn L., Ananthanarayanan V., Gann P.H. Evidence for field cancerization of the prostate. Prostate 2009, 69(13):1470-1479.
278. Vlajinac H.D., Marinkovic J.M., Ilic M.D., Kocev N.I. Diet and prostate cancer: a case-control study. Eur. J. Cancer 1997, 33(1):101-107.
279. Lu Q.Y., Hung J.C., Heber D., Go V.L., Reuter V.E., Cordon-Cardo C., et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2001, 10(7):749-756.
280. Stevens V.L., Rodriguez C., Pavluck A.L., McCullough M.L., Thun M.J., Calle E.E. Folate nutrition and prostate cancer incidence in a large cohort of US men. Am. J. Epidemiol. 2006, 163(11):989-996.
281. Jain M.G., Hislop G.T., Howe G.R., Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr. Cancer 1999, 34(2):173-184.
282. McCann S.E., Ambrosone C.B., Moysich K.B., Brasure J., Marshall J.R., Freudenheim J.L., et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr. Cancer 2005, 53(1):33-41.
283. Weinstein S.J., Stolzenberg-Solomon R., Pietinen P., Taylor P.R., Virtamo J., Albanes D. Dietary factors of one-carbon metabolism and prostate cancer risk. Am. J. Clin. Nutr. 2006, 84(4):929-935.
284. Lewis J.E., Soler-Vila H., Clark P.E., Kresty L.A., Allen G.O., Hu J.J. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr. Cancer 2009, 61(2):216-224.
285. Hultdin J., van Guelpen B.R., Bergh A., Hallmans G., Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int. J. Cancer 2005, 113(5):819-824.
286. Weinstein S.J., Hartman T.J., Stolzenberg-Solomon R., Pietinen P., Barrett M.J., Taylor P.R., et al. Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol. Biomarkers Prev. 2003, 12(11 Pt. 1):1271-1272.
287. Johansson M., Appleby P.N., Allen N.E., Travis R.C., Roddam A.W., Egevad L., et al. Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol. Biomarkers Prev. 2008, 17(2):279-285.
288. Zhang Y., Coogan P., Palmer J.R., Strom B.L., Rosenberg L. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control 2009, 20(5):691-698.
289. Johansson M., van Guelpen B.R., Vollset S.E., Hultdin J., Bergh A., Key T., et al. One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. Cancer Epidemiol. Biomarkers Prev. 2009, 18(5):1538-1543.
290. Dowd J.B., Aiello A.E. Did national folic acid fortification reduce socioeconomic and racial disparities in folate status in the US?. Int. J. Epidemiol. 2008, 37(5):1059-1066.
291. Collin S.M., Martin R.M., Metcalfe C., Gunnell D., Albertsen P.C., Neal D., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008, 9(5):445-452.
292. Kasperzyk J.L., Fall K., Mucci L.A., Hakansson N., Wolk A., Johansson J.E., et al. One-carbon metabolism-related nutrients and prostate cancer survival. Am. J. Clin. Nutr. 2009, 90(3):561-569.
293. Bostwick D.G., Burke H.B., Djakiew D., Euling S., Ho S.M., Landolph J., et al. Human prostate cancer risk factors. Cancer 2004, 101(Suppl. 10):2371-2490.
294. Kristal A.R., Peters U., Potter J.D. Is it time to abandon the food frequency questionnaire?. Cancer Epidemiol. Biomarkers Prev. 2005, 14(12):2826-2828.
295. Jenab M., Slimani N., Bictash M., Ferrari P., Bingham S.A. Biomarkers in nutritional epidemiology: applications, needs and new horizons. Hum. Genet. 2009, 125(5-6):507-525.
296. Martinez M.E., Marshall J.R., Giovannucci E. Diet and cancer prevention: the roles of observation and experimentation. Nat. Rev. Cancer 2008, 8(9):694-703.
297. Cole B.F., Baron J.A., Sandler R.S., Haile R.W., Ahnen D.J., Bresalier R.S., et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007, 297(21):2351-2359.
298. Ebbing M., Bleie O., Ueland P.M., Nordrehaug J.E., Nilsen D.W., Vollset S.E., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008, 300(7):795-804.
299. Collin S.M., Metcalfe C., Refsum H., Lewis S.J., Zuccolo L., Smith G.D., et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2010, 19(6):1632-1642.
300. Collin S.M., Metcalfe C., Refsum H., Lewis S.J., Davey Smith G., Cox A., et al. Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2010, 19(11):2833-2838.
301. Fu Y.M., Yu Z.X., Li Y.Q., Ge X., Sanchez P.J., Fu X., et al. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutr. Cancer 2003, 45(1):60-73.
302. Fu Y.M., Zhang H., Ding M., Li Y.Q., Fu X., Yu Z.X., et al. Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells. J. Cell. Physiol. 2006, 209(2):522-534.
303. Fu Y.M., Yu Z.X., Lin H., Fu X., Meadows G.G. Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells. J. Cell. Physiol. 2008, 217(1):184-193.
304. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354(15):1578-1588.
305. Witte J.S. Prostate cancer genomics: towards a new understanding. Nat. Rev. Genet. 2009, 10(2):77-82.
306. Collin S.M., Metcalfe C., Zuccolo L., Lewis S.J., Chen L., Cox A., et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2009, 18(9):2528-2539.
307. Collin S.M., Metcalfe C., Palmer T.M., Refsum H., Lewis S.J., Smith G.D., et al. The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. Int. J. Mol. Epidemiol. Genet. 2011, 2(4):316-327.
308. Tomaszewski J.J., Cummings J.L., Parwani A.V., Dhir R., Mason J.B., Nelson J.B., et al. Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Prostate 2011, 9:10.
309. Kawakami K., Ruszkiewicz A., Bennett G., Moore J., Watanabe G., Iacopetta B. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin. Cancer Res. 2003, 9(16 Pt. 1):5860-5865.
310. Pufulete M., Al-Ghnaniem R., Leather A.J., Appleby P., Gout S., Terry C., et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 2003, 124(5):1240-1248.
311. Pufulete M., Al-Ghnaniem R., Khushal A., Appleby P., Harris N., Gout S., et al. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut 2005, 54(5):648-653.
312. Wallace K., Grau M.V., Levine A.J., Shen L., Hamdan R., Chen X., et al. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev. Res. (Phila.) 2010, 3(12):1552-1564.
313. Schlomm T., Hellwinkel O.J., Buness A., Ruschhaupt M., Lubke A.M., Chun F.K., et al. Molecular cancer phenotype in normal prostate tissue. Eur. Urol. 2009, 55(4):885-890.
314. Yao V., Berkman C.E., Choi J.K., O'Keefe D.S., Bacich D.J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 2010, 70(3):305-316.